RFK Jr. proposes FDA look the other way on unproven peptides, report says
FDA scientists said none of the popular drugs have been proven safe or effective.
Robert F. Kennedy Jr. has proposed that the Food and Drug Administration (FDA) adopt a lenient approach towards unproven peptide drugs, according to a recent report. This proposal, submitted for review under the White House, would permit the FDA to exercise "enforcement discretion" on certain peptide drugs, effectively allowing them to bypass current restrictions and commence production without rigorous safety and efficacy testing.
The decision is anticipated to benefit specialty pharmacies, which have shown interest in manufacturing these peptides, as they would be shielded from potential FDA penalties. The FDA's decision, however, has not been without criticism, with FDA staff scientists raising concerns that the peptides have not undergone sufficient scrutiny to validate their safety and efficacy, and may potentially pose risks to consumers.
The Department of Health and Human Services, which governs the FDA, has yet to provide a response to inquiries about the proposed policy.
Written by urgent.news from Ars Technica Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
